Veeva's AI Gambit: Agentic MLR Aims to Remake Life Sciences Compliance

PLEASANTON, CA – June 23, 2026

In the heavily regulated world of life sciences, the Medical, Legal, and Regulatory (MLR) review process has long been a notorious bottleneck. This mandatory, multi-stage gauntlet, designed to ensure all promotional and medical materials are accurate and compliant, is a critical safeguard. However, its manual, labor-intensive nature routinely delays the delivery of vital information to healthcare professionals and patients. Today, Veeva Systems, a dominant force in the industry's cloud infrastructure, made a decisive move to dismantle that bottleneck, announcing its acquisition of Danish AI pioneer Copli and the immediate launch of Veeva Falcon MLR.

The new solution comes with a bold promise: to leverage “agentic MLR” to eliminate 70% or more of manual review labor within five years. This isn't just about speeding up a workflow; it's a strategic play aimed at fundamentally re-architecting how compliance is managed. "The MLR process has long been a significant bottleneck in getting critical information to patients and doctors," said Emma Hyland, vice president of Veeva Commercial Content. With Falcon MLR, the company claims it can automate routine labor, allowing human reviewers to ascend from tactical checkers to strategic advisors.

From Automation to Autonomy: The Dawn of Agentic MLR

The term “agentic AI” signals a significant departure from the automation tools and predictive analytics that have so far defined AI's role in the enterprise. Where traditional AI might flag a potential issue for a human to resolve, an agentic system is designed to understand a goal, create a plan, and execute a series of actions to achieve it. It moves from suggestion to execution.

In the context of MLR, this means a system of intelligent agents can perform rigorous, multi-step compliance checks autonomously. Veeva Falcon MLR can analyze a promotional document, cross-reference its claims against an approved drug label, verify it against local regulations, and flag or even correct inconsistencies—all with minimal human intervention. This is made possible by using Large Language Models (LLMs) not just to generate text, but as a reasoning engine or “brain” to orchestrate tasks.

“Our breakthrough with agentic MLR marks a fundamental shift in commercial and medical content review and approval,” said Jacob Scheel-Bech, the former CEO of Copli who now joins Veeva. “As part of Veeva, we can scale our vision for MLR transformation.”

This shift from automation to autonomy is critical. While many industries are experimenting with AI agents for low-risk tasks like scheduling meetings or summarizing documents, Veeva is deploying them into one of the most high-stakes, zero-error-tolerance environments in business. The system's success will hinge on its ability to move beyond simple pattern matching and demonstrate genuine contextual understanding of complex regulatory frameworks.

A Strategic Moat in the Cloud

Veeva's acquisition of Copli and the launch of Falcon MLR is far more than a product line extension; it's a calculated strategic maneuver to fortify its dominance. Veeva's Vault Platform, particularly its PromoMats application, is the de facto content management system for a vast majority of the life sciences industry, serving over 1,500 customers from global pharmaceutical giants to emerging biotechs.

By integrating Falcon MLR directly into PromoMats, Veeva is not asking its customers to adopt a new platform. Instead, it is embedding a powerful, next-generation capability directly into the system they already rely on. This integration is Veeva's trump card. While competitors like Narrativa and Indegene are also developing agentic AI solutions, they face the uphill battle of convincing companies to either adopt a new system or manage a complex integration. Veeva is simply upgrading the engine inside the car everyone is already driving.

This move deepens the company's competitive moat, making its ecosystem even stickier and more indispensable. For leaders evaluating their technology stack, the promise of a seamless, AI-powered compliance engine within their existing infrastructure presents a compelling value proposition. It’s a classic systems-based play, reinforcing the central platform by solving one of its users' most significant operational pain points.

Navigating the High-Stakes Gauntlet of Regulation and Trust

Despite the technological promise, the path to 70% automation is fraught with challenges. The primary hurdles are not technical but are rooted in trust, transparency, and the unforgiving nature of regulatory compliance. In an industry where a single misplaced claim can lead to severe penalties and patient harm, the question of liability for an AI's error is paramount.

Regulatory bodies like the FDA and EMA are still developing comprehensive guidelines for the use of AI in core commercial and medical processes. Any autonomous system operating in this space will require impeccable audit trails and a high degree of explainability (XAI)—the ability to articulate precisely why a decision was made. Black-box algorithms are non-starters.

Industry experts caution that successful adoption will require a robust “human-in-the-loop” framework. The goal of agentic MLR is not to eliminate human oversight but to concentrate it where it matters most. Autonomous agents can handle the high-volume, repetitive checks, freeing human experts to focus on nuanced interpretations, ambiguous edge cases, and final sign-off authority. Trust must be earned, and that will only come from systems that are transparent, reliable, and demonstrably safe. The effectiveness of these AI agents also relies heavily on the quality of the underlying data and the clarity of the workflow definitions they operate on, demanding that organizations maintain pristine data hygiene.

The Human Variable: Reskilling for a New Compliance Era

The stated goal of eliminating 70% of manual labor will inevitably raise concerns about job displacement. However, the more likely outcome is a profound evolution of the roles of MLR professionals. As Emma Hyland noted, the objective is to elevate reviewers into “strategic advisors.”

This represents a fundamental shift in the skills required to succeed in a compliance-focused career. The future MLR professional will spend less time on line-by-line proofreading and more time on strategic counsel. Their expertise will be needed to train and validate the AI models, manage escalations for complex cases the AI cannot resolve, and advise marketing and medical teams on how to create compliant content from the outset. Their role will evolve from gatekeeper to enabler.

For business leaders, this transition necessitates a proactive approach to workforce development. Companies that invest in upskilling their regulatory teams—training them in AI oversight, data analysis, and strategic communication—will be best positioned to capitalize on the efficiency gains. The human variable remains the most critical component. The technology is a powerful tool, but its ultimate value will be unlocked by the skilled professionals who learn to wield it effectively, transforming a burdensome cost center into a source of strategic advantage.